



(12) Translation of
european patent specification

(11) NO/EP 2242512 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/28 (2006.01)
A61K 39/00 (2006.01)
A61K 39/395 (2006.01)
C07K 16/18 (2006.01)
C07K 16/46 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.09.12
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.04.27
(86)	European Application Nr.	09701993.9
(86)	European Filing Date	2009.01.15
(87)	The European Application's Publication Date	2010.10.27
(30)	Priority	2008.01.15, US, 11324 P 2008.08.22, US, 189786 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
(73)	Proprietor	The Board of Trustees of the Leland Stanford Junior University, Office of the General Counsel Building 170 3rd Floor, Main Quad P.O. Box 20386, Stanford CA 94305-2038, US-USA
(72)	Inventor	JAISWAL, Siddhartha, 232 Newbury Street, Apt.21, Boston, MA 02116, US-USA WEISSMAN, Irving, L., 747 Santa Ynez Street, Stanford, CA 97305, US-USA JAMIESON, Catriona, Helen, M., Moores University of California San Diego Cancer Center, MC 0820, 3855 Healy Science Drive, La Jolla, CA 92093-0820, US-USA MAJETI, Ravindra, Stanford Institute for Stem Cell Bio andRegenerative Medicine1050 Arastradero RoadBuilding A, Stanford,California 94304, US-USA
(74)	Agent or Attorney	Oslo Patentkontor AS, Postboks 7007 Majorstua , 0306 OSLO, Norge

(54)	Title	METHODS FOR MANIPULATING PHAGOCYTOSIS MEDIATED BY CD47
(56)	References Cited:	EP-A1- 1 693 385, US-A1- 2005 118 164, US-A1- 2006 239 910, US-A1- 2007 111 238, US-A1- 2007 113 297, PARTHA MANNA ET AL: "CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 1026-1036, XP55030076, ISSN: 0008-5472, Y. LIU ET AL: "Signal Regulatory Protein (SIRPalpha), a Cellular Ligand for CD47, Regulates Neutrophil Transmigration", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 12, 15 March 2002 (2002-03-15), pages 10028- 10036, XP55030073, ISSN: 0021-9258, DOI: 10.1074/jbc.M109720200 RAVINDRA MAJETI ET AL: "CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells", DEVELOPMENTAL CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 138, no. 2, 23 July 2009 (2009-07-23) , pages 286-299, XP002632714, ISSN: 1097-4172, DOI: 10.1016/J.CELL.2009.05.045 [retrieved on 2009-07-23], S. B. WILLINGHAM ET AL: "The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 17, 26 March 2012 (2012-03-26), pages 6662-6667, XP55029983, ISSN: 0027-8424, DOI: 10.1073/pnas.1121623109 MAJETI RAVINDRA ET AL: "CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 1 November 2008 (2008-11-01), page 284, XP009160228, ISSN: 0006-4971 BROOKE ET AL.: 'Human Lymphocytes Interact Directly with CD47 Through a Novel Member of the Signal Regulatory Protein (SIRP) Family' JOURNAL OF IMMUNOLOGY vol. 173, 2004, pages 2562 - 2570, XP008138739 JAMIESON ET AL.: 'BLOOD (ASH Annual Meeting abstracts)', vol. 106, 2005 article JAMIESON ET AL.: 'Increased expression of CD47 is a constant marker in mouse and human myeloid leukemias', XP008138745 PETTERSEN R F ET AL: "CD47 SIGNALS T CELL DEATH", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 162, 1 January 1999 (1999-01-01), pages 7031-7040, XP002940659, ISSN: 0022-1767 X. W. ZHAO ET AL: "Is targeting of CD47-SIRP enough for treating hematopoietic malignancy?", BLOOD, vol. 119, no. 18, 3 May 2012 (2012-05-03), pages 4333-4334, XP055116565, ISSN: 0006-4971, DOI: 10.1182/blood-2011-11-391367 P. P. MANNA ET AL: "The Mechanism of CD47-Dependent Killing of T Cells: Heterotrimeric Gi-Dependent Inhibition of Protein Kinase A", THE JOURNAL OF IMMUNOLOGY, vol. 170, no. 7, 1 April 2003 (2003-04-01) , pages 3544-3553, XP055116597, ISSN: 0022-1767, DOI: 10.4049/jimmunol.170.7.3544 M. P. CHAO ET AL: "Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia", CANCER RESEARCH, vol. 71, no. 4, 15 February 2011 (2011-02-15), pages 1374-1384, XP055029988, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-2238 JAISWAL S ET AL: "Macrophages as mediators of tumor immunosurveillance", TRENDS IN IMMUNOLOGY, ELSEVIER LTD. * TRENDS JOURNALS, GB, vol. 31, no. 6, 1 June 2010 (2010-06-01), pages 212-219, XP027079216, ISSN: 1471- 4906, DOI: 10.1016/J.IT.2010.04.001 [retrieved on 2010-06-01] X. W. ZHAO ET AL: "CD47-signal regulatory protein- (SIRP) interactions form a barrier for antibody-mediated tumor cell destruction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 45, 8 November 2011 (2011- 11-08), pages 18342-18347, XP055055636, ISSN: 0027-8424, DOI: 10.1073/pnas.1106550108

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. CD47-inhibitor for anvendelse i en fremgangsmåte for behandling av kreft ved å øke fagocytose av levende tumorceller i et menneske, hvor nevnte inhibitor er et antistoff som binder CD47 på overflaten av en levende tumorcelle og derved
5 hindrer bindingen av nevnte CD47 til en SIRPα-reseptor på overflaten av en fagocytt-celle for derved å målrette den levende tumorcelle for fagocytose.
2. CD47-inhibitor for anvendelse ifølge krav 1, hvor tumorcellene er akutte leukemi-celler.
3. CD47-inhibitor for anvendelse ifølge krav 2, hvor tumorcellene er AML- eller
10 ALL-celler.
4. CD47-inhibitor for anvendelse ifølge krav 1, hvor tumorcellene er faste tumorceller.
5. CD47-inhibitor for anvendelse ifølge krav 4, hvor de faste tumorcellene er karsinom-celler.
- 15 6. CD47-inhibitor for anvendelse ifølge krav 5, hvor karsinom-cellene er ovarie-karsinom- eller blære-karsinom-celler.
7. CD47-inhibitor for anvendelse ifølge krav 5, hvor de faste tumor-cellene er glioblastom-celler.
8. CD47-inhibitor for anvendelse ifølge krav 1, hvor nevnte antistoff er
20 konjugert til et cytotoxisk middel.
9. CD47-inhibitor for anvendelse ifølge krav 8, hvor nevnte cytotoxiske middel er valgt fra gruppen bestående av en radioaktiv isotop, et kjemoterapeutisk middel og et toksin.
10. CD47-inhibitor for anvendelse ifølge krav 1, hvor antistoffet er et bispesifikt
25 antistoff.
11. CD47-inhibitor for anvendelse ifølge krav 1 eller krav 8, hvor CD47-inhibitoren målretter eller utarmer akutt leukemi stamceller i et menneske.